Emcitate
(Tiratricol)Phase 2Small molecule
Emcitate is one of 50 small molecule programs targeting Trial. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
49
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
133 competitors in Trial
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Herceptin
RochePhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Camptosar
PfizerPhase 3
Eloxatin
TevaPhase 3
Vectibix
AmgenPhase 3
Perjeta
RochePhase 3
Tarceva
OOSI Pharmaceuticals
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Sep 28, 2026
EMCITATE
NDA NDA220963
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tiratricol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details